Are Radiopharmaceuticals Going to Change the Future Prospects of Cancer Treatment?

Highlights:

• Introduction to radiopharmaceuticals
• Diverse use cases of these specialized drugs
• Recent innovations in radiopharmaceuticals
• AstraZeneca’s next-gen RCs

Radiopharmaceuticals are specialized drugs that are used in both the diagnosis and treatment of various medical conditions, especially cancer. These are a unique class of drugs that contain radioactive isotopes, enabling healthcare providers to deliver radiation directly to cancerous cells. These drugs have three building blocks, one is a radioactive molecule, a targeting molecule that recognizes cancer cells, and a linker that joins the two.  The radioactive isotopes emit gamma-rays that are detected by special imaging equipment, such as positron emission tomography, and single photon emission computed tomography (SPECT) scanners.

Once these drugs enter the bloodstream, the medications travel throughout the body and accumulate in targeted areas like tumor sites and start emitting radiation. The radiation damages the DNA of rapidly multiplying cancer cells, restrains their ability to grow, and destroys them. The emitted radiation is captured by a PET or SPECT scanner, which further generates detailed images to help physicians identify the location, size, and extent of cancerous tissues.

On the other hand, it is targeted treatment approach that allows for the direct delivery of radiation to a tumor cell, while minimizing any damage to the surrounding of healthy tissues. In addition, this specific treatment is also beneficial in treating cancer cells that have spread throughout the body.

Radiopharmaceuticals in medicine

Radiopharmaceuticals play a key role in diagnostic imaging. They are often referred to as "tracers" because they provide a way to observe and track physiological processes. For instance, technetium-99m is one of the most commonly used isotopes in nuclear medicine for imaging various organs and identifying conditions such as cancer. The emitted gamma rays from these isotopes allow healthcare providers to obtain non-invasive images that reflect organ function and detect abnormalities.

In addition to diagnostics, radiopharmaceuticals are also employed in treatment protocols. They deliver targeted radiation directly to tumors, minimizing harm to surrounding healthy tissues. This method is particularly effective for cancers that have spread extensively, including prostate cancer with bone metastases and specific types of thyroid cancer. The therapeutic action can complement other treatments like chemotherapy and hormone therapy, enhancing overall efficacy.

How are advances in radiopharmaceuticals enhancing cancer treatment modalities?

In the last few years, the radiopharmaceutical market has experienced significant growth due to a rise in cases of cancer among individuals worldwide. This has increased the demand for advanced diagnostic imaging solutions to identify the severity of the disease and offer customized treatment alternatives.

According to recent studies, innovations in targeting mechanisms have transformed the landscape by optimizing diagnosis and targeted therapies. Continuous research and development activities have enhanced the design of radiolabeled nanocarriers, such as liposomes and polymers, to improve their circulation time and tumor penetration. This involves utilizing the enhanced permeability and retention effect alongside active targeting strategies where molecules bind to specific receptors on cancer cells.

On the other hand, the development of new stimulus-responsive release systems has allowed for the controlled release of radiopharmaceuticals. These systems can respond to internal or external stimuli such as temperature, pH, and light to enhance selectivity and therapeutic effectiveness.

In addition, a new Coordinated Research Project by the IAEA aims to develop a new generation of technetium-99m radiopharmaceuticals, which is expected to create waves in the field of nuclear medicine. This project focuses on creating kits for various applications, including imaging for prostate cancer using PSMA ligands and other innovative tracers for neurological diseases.

Many researchers are also exploring combinations of radiopharmaceuticals with other treatment modalities, such as immunotherapy and radiation sensitizers. These combinations aim to enhance the overall effectiveness of cancer treatments by making tumors more responsive to radiation. For example, combining lutetium Lu 177-dotatate with PARP inhibitors may enhance the effectiveness of radiation therapy by blocking DNA repair in tumor cells.

AstraZeneca expanded its oncology portfolio with Fusion Pharmaceuticals

In March 2024, AstraZeneca, a science-led biopharmaceutical business announced its acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company. This agreement showcases AstraZeneca’s initiative to deliver effective cancer treatment solutions and improve patient outcomes by developing next-generation radio-conjugates (RCs), replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. RCs have the potential benefits over traditional radiotherapy which include minimized damage to healthy cells, enabling access to tumors that are not reachable through external beam radiation. Through this acquisition, the company aims to expand its oncology portfolio by introducing the Fusion pipeline of RCs, providing new treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC).

Winding up

Radiopharmaceuticals represent a remarkable innovation in modern medicines, combining diagnostic imaging with targeted therapy. Their ability to provide detailed insights into disease processes while simultaneously offering treatment options emphasizes their significance in oncology and other medical fields. Moreover, the increasing investment in building a robust healthcare infrastructure and the growing demand for precision medicine are prime factors expected to boost the development of novel drugs in the forthcoming years.

To gain more details about the upcoming advancements in radiopharmaceuticals, contact our esteemed industry analysts today!

Related Post